Oral Medication Option May Lead to Improved Treatment Adherence in Patients with Psoriatic Arthritis
September 4th 2014Until apremilast was approved earlier this year, patients with psoriatic arthritis had to rely primarily on injectable therapies, which contributed to less than optimal treatment adherence in many patients.
Read More
Apremilast and the Future of Psoriatic Arthritis Treatment
August 21st 2014When it was approved by the FDA in March 2014, apremilast became the first oral medication approved for the treatment of psoriatic arthritis (PsA). Data from clinical trials showed it to be an effective option for patients, with a safer side effect profile than currently used PsA treatments.
Read More
Weight Loss Improves Disease Management in Patients with Psoriatic Arthritis
July 1st 2014Study results show that obese patients with psoriatic arthritis who were treated with tumor necrosis factor-alpha blockers who also lost at least 5 percent of their bodyweight from baseline were much more likely to achieve minimal disease activity.
Read More
Cardiovascular Risk Factors Associated with Psoriatic Arthritis Complicate Treatment Decisions
May 28th 2014Patients with psoriatic arthritis may be at increased risk for cardiovascular disease, so physicians must carefully weigh the pros and cons of treatment with corticosteroids and other proatherogenic drugs.
Read More